I den store subgruppe af patienter, som gennemgik cancerkirurgi (69% af et
In the large subgroup of patients undergoing cancer surgery (69% of the patient population), the VTE rate was 4.7% in the fondaparinux group, versus 7.7% in the dalteparin group.